Discover Great Companies Discover Great Clients
Popularity  1.7万   |   Followers  5   |   Feedback  3 Claim this company

Global integrated biopharmaceutical enterprise

No.45 Shanghai Popularity Ranking No.19 Pudong New Area No.1 Antibodies No.1 Yi Yao Xin Yao No.1 Xin Yao R&D No.1 Pharmaceutical R&D No.1 Kang Gan Ran Yao Products No.1 Qu Yu Jing Ji No.2 Lin Chuang Shi Yan No.2 Vaccines Technology No.2 Rare Diseases No.2 Jia Ting Yi Sheng No.2 Ren Yong Yi Miao No.3 Pharmaceutical
More

Company Overview

  • Nature: Foreign-funded Enterprise Size: More than 10,000 emp Founded: 19年
  • Industry: Pharmaceuticals/Biotechnology 、 Healthcare/Nursing/Health
  • Full name: AstraZeneca Investment (China) Co., Ltd.。

Development Stage

  • Ranking: Ranked #45 in Shanghai by popularity Ranked #1 in Shanghai Antibodies Company by popularity Ranked #1 in Shanghai Yi Yao Xin Yao Company by popularity Ranked #1 in Shanghai Xin Yao R&D Company by popularity Ranked #1 in Shanghai Pharmaceutical R&D Company by popularity
  • Honors: 2023中国服务业企业慈善公益500强
  • News: 2026-03-02:阿斯利康陈冰:创新药大额BD仍会出现,关键看“互补性”|2026医疗展望。
  • Salary: 46.6% of positions earn 10-20K, In 2026 vs last yeargrew by 40%.。Master's salary: ¥26.7K, Doctorate salary: ¥40.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 35.6%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 18.2%, "Computer/Network/Technology": 9.5%。
  • Recruiting: In 2026 vs 2025grew by 97%. Demand for highly educated talent: Master's: 106, Doctorate: 19.
  • Requirement: Education: 本科 leads with 65.8%. Experience: 1-3年 leads with 32.8%.
  • Region: Distributed across 58 regions, 上海: 22.3%, 无锡: 6.9%, 北京: 6.1%, 青岛: 4.3%.

About the Company

[Summary] Global integrated biopharmaceutical enterprise

2023 marks the 30th year since AstraZeneca entered China. Since 1993, AstraZeneca has adhered to its original aspiration of "patient-centricity," grounded in science, continuously expanding the frontiers of science, and driving innovative practices and sustainable development across drug R&D, production operations, and business models. Over the past three decades, AstraZeneca has remained committed to becoming a localized multinational pharmaceutical company that "brings in, takes root, and goes global." Leveraging its global advantageous resources and deep insights into the local Chinese pharmaceutical market, it continuously gathers global wisdom and strength while helping "Chinese innovation" reach the world, fulfilling the long-term commitment of "rooted in China, serving China, benefiting the globe."
AstraZeneca's China headquarters and the Global R&D China Center are located in Shanghai, with global production supply bases in Wuxi, Taizhou, and Qingdao, supplying high-quality medicines to approximately 70 global markets. To date, the company has cumulatively invested nearly USD 2 billion in China, and in recent years has established regional headquarters in Beijing, Guangzhou, Hangzhou, Chengdu, and Qingdao. Over the past 30 years, AstraZeneca has consistently focused on therapeutic areas of urgent need for Chinese patients, including oncology, cardiovascular, metabolic, renal, respiratory, digestive, rare diseases, vaccine antibodies, and autoimmune diseases, bringing nearly 40 innovative drugs to China.
After 30 years of deep cultivation in China, AstraZeneca continues to hold a positive outlook on China's R&D and innovation capabilities, increasing deployment and investment to elevate the speed and height of R&D innovation in China. In 2002, AstraZeneca pioneered global multicenter clinical trials in China; in 2007, it invested in establishing the China Innovation Center, focusing on unmet health needs of Chinese patients; in 2013, it established the China New Drug Development Department to support clinical development and launch of AstraZeneca's innovative drugs in China; in 2017, AstraZeneca partnered with SDIC Innovation to establish Dizal (Jiangsu) Pharmaceutical Co., Ltd., accelerating the pace of local new drug R&D; in 2019, it upgraded the New Drug Development Department to the Global R&D China Center, officially launched in Shanghai in 2021, deeply participating in global R&D and actively advancing global new drug development with strong Chinese R&D capabilities. Currently, there are over 180 projects in the China R&D pipeline, with a 100% synchronization rate for key projects with global R&D, and plans to introduce at least 15 new drugs (NMEs) in China within 5 years, with approximately 80 new drugs or new indications expected to be approved. It is also making forward-looking investments in disease areas where there remains substantial unmet medical need in China, collaborating to drive Chinese local innovation to the global stage and accelerate the delivery of high-quality innovative drugs to benefit more patients.
AstraZeneca thrives in symbiosis with the industry, joining forces with cross-sectoral entities including government, industry, academia, research, medical, and investment sectors. Guided by clear planning and innovation-driven development, it builds an international innovative health ecosystem through the "troika" of innovation: the China Centre for Innovative Healthcare (CCiC), the International Life Science Innovation Campus (iCampus), and the AstraZeneca CICC Medical Industry Fund. These efforts jointly promote regional economic and health industry long-term development. Currently, the diagnostic-treatment integrated innovative models supported by the CCiC have been implemented in thousands of hospitals nationwide, with some solutions also expanding abroad to more countries and regions. The iCampus integrates local industrial advantages to create a one-stop empowerment platform, forming a nationwide collaborative life science innovation ecosystem network, welcoming over 110 domestic and international enterprises. The AstraZeneca CICC Medical Industry Fund currently manages over RMB 3 billion in assets and has successfully invested in nearly 20 companies. In 2022, the fund initiated a new chapter of regional expansion, providing multidimensional empowerment for Chinese innovation across cycles and regions.
As a thirteen-time consecutive Outstanding Employer, cultivating local talent remains the cornerstone of AstraZeneca's long-term development in China. We actively develop domestic and international, cross-disciplinary talent development programs, uphold corporate values of "Science-led, Patient-first, Win with determination, Win with integrity, and Pioneer with courage," providing infinite possibilities for nurturing diverse local innovative talent with a global vision, pursuit of excellence, openness to collaboration, and fearlessness. Simultaneously, AstraZeneca in China highly fulfills its corporate social responsibility, actively engaging in diverse public welfare initiatives to jointly promote green and sustainable development for humanity, society, and the planet.
Standing at a new starting point of 30 years of establishment, AstraZeneca remains fully committed to forging ahead with determination, deepening investments in China, actively playing the role of an international bridge, advancing both "bringing in" and "going global" to benefit China and the world, joining forces to draw a blueprint for the health of all humanity.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

AstraZeneca How Fast Is Hiring Growing? (836 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 267%
  • 2024: Up 2000%
  • 2023: Up 57%
AstraZeneca Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
AstraZeneca Campus Recruitment & Advanced Degree Talent Demand
Graduates 4 Interns 10 Master's 106 Doctorate 19
No.190
Company Recruitment Ranking in Shanghai 򀀩
No.1387
Recruitment Growth Ranking in Shanghai 򀀩
No.286
Graduate Talent Ranking in Shanghai 򀀩
No.111
Intern Talent Ranking in Shanghai 򀀩
Note: How fast is hiring at AstraZeneca Investment (China) Co., Ltd. growing? AstraZeneca2026: 1668 openings (up 97%), 2025: 847 openings (up 267%), 2024: 231 openings (up 2000%), 2023: 11 openings (up 57%), 2022: 7 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

AstraZeneca Master's Degree Job Demand Analysis

(More)
How fast is master's hiring at AstraZeneca Investment (China) Co., Ltd. growing? AstraZenecaMaster's recruitment over the years: 2025: 41 openings (up 413%), 2024: 8 openings. AstraZeneca master talent ranking in Shanghai: #23, AstraZeneca master salary mostly around 20-50K.

AstraZeneca Doctoral Degree Job Demand Analysis

(More)
+525%
Growth Rate
2026 vs 2025
AstraZeneca Doctoral Hiring by Year: 2026 — 21 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at AstraZeneca Investment (China) Co., Ltd. growing? AstraZenecaDoctorate recruitment over the years: 2026: 25 openings (up 378%), 2025: 4 openings (up 413%). AstraZeneca doctorate talent ranking in Shanghai: #40, AstraZeneca doctorate salary mostly around 30-50K and above.

AstraZeneca R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at AstraZeneca Investment (China) Co., Ltd.? Based on an analysis of AstraZeneca's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 35.6%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 18.2%, "Computer/Network/Technology": 9.5%, "Electronics/Electrical/Communication Technology": 8.4%, "Other (R&D and Technical)": 0.6%, "Surveying and Mapping Technology": 0.4%. For reference only.

AstraZeneca — What Are the Salaries Like? (1459 records)

Manage
salary range: 2K - 50K, 46.6% of roles pay ¥10-20K
Note: salary statistics are based on 1459 salary records from the past year and depend on the job sample. For reference only.
How is the salary at AstraZeneca Investment (China) Co., Ltd.?AstraZeneca46.6% of positions earn 10-20K, Fresh graduate salary: ¥6.4K。医疗卫生/美容保健类 average salary ¥13.4K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of AstraZeneca

(More)
Are salaries high at AstraZeneca Investment (China) Co., Ltd.? We provide: Medical Representative, MA, Pharmaceutical Sales Representative, Test Engineer, Intern, Organization Culture Specialist, Medical Science Liaison, RA, PR, Medical Science Liaison, Process Engineer, CTO, Investor Relations, ee, Executive Assistant, Industrial Engineer, Brand, Retail, PA, QC. Click to view detailed salary analysis by job.

AstraZeneca — Fortune 500? (More)

Yes, ranked in 中国服务业企业慈善公益500强:

  • NO.309 2023中国服务业企业慈善公益500强 >

AstraZeneca honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 医疗卫生/美容保健类
    34.1% of total 34.1%
  • 销售类
    32.1% of total 32.1%
  • 其他类
    18% of total 18%
  • 生物/制药/化工/环保类
    17.4% of total 17.4%

Education

  • 本科
    65.8% of total 65.8%
  • 大专
    20.1% of total 20.1%
  • 硕士
    11.6% of total 11.6%
  • 博士
    1.5% of total 1.5%

Experience

  • 1-3年
    32.8% of total 32.8%
  • 不限
    29.5% of total 29.5%
  • 3-5年
    21.4% of total 21.4%
  • 5-10年
    15.3% of total 15.3%
View Detailed Analysis

What does AstraZeneca Investment (China) Co., Ltd. require? Who is AstraZeneca hiring? AstraZeneca recruitment: 医疗卫生/美容保健类占比最多占34.1%,其次是销售类占32.1%. What education can get in at AstraZeneca? 本科占比最多占65.8%,其次是大专占20.1%. High education required at AstraZeneca? 硕士占11.6%,博士占1.5%. Work experience required at AstraZeneca? 1-3年占比最多占32.8%,其次是不限占29.5%. Where are the job locations at AstraZeneca? 上海占比最多占22.3%,其次是无锡占6.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 12,000万(美元)
Legal Representative: 林骁
Date Established:
Credit Code: 91310000717881028D
Registered Address: 中国(上海)自由贸易试验区亮景路199号

Partners & Suppliers

博纳精密为阿斯利康提供吸入器装置,用于哮喘和COPD药物交付。 Source
供应商 跨国制药企业
为阿斯利康中国临床研究提供患者招募与数据管理服务 Source
供应商 临床研究服务
采用丹望类器官进行药物敏感性测试 Source
供应商 制药企业
采购毕得医药分子砌块,用于新药开发项目 Source
供应商 分子砌块与科研试剂客户-制药企业
签署战略合作协议,提供化学合成与药物研发服务 Source
供应商 小分子药物研发服务

People who follow AstraZeneca also follow

AstraZeneca Competitors (Similar Companies)

“Pioneering innovation, benefiting patients”
“Continuously innovating to bring patients medicines that significantly”
“Research, development, and production of anti-tumor and surgical medic”
医药 医药工业 创新药 药物研发
“Focused on three major fields: healthcare, life science, and electroni”
“Improving people's quality of life”
制药/药业 抗肿瘤药 肿瘤检测 神经系统疾病药物
“Dedicated to the research and development of molecularly targeted drug”
“To develop high-quality biologics that are accessible and affordable f”
“A renowned enterprise in China's liver disease and anti-tumor fields”
制药/药业 医药 生产 医疗人工智能/AI
抗感染药物 中枢神经药 医药 药物研发
“Seek and strive, protect and heal all beings”
医药 药物研发 生物制药 临床前研究
医药 诊断试剂 疫苗 创新药

Discover Great Companies, Discover Great Clients

上海公司名录 上海“Pudong New Area”公司名录 上海“医药”公司名录 上海“生命科学”公司名录 上海“抗体”公司名录 上海“药物研发”公司名录 上海“疫苗”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates